Key facts
- This page summarizes Jason Hsu's Form 4 filing for Immix Biopharma, Inc. (IMMX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 29 May 2026, 17:05.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Award
No transaction description listed
No transaction description listed
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Additional SEC filing notes
Footnote F1
The Reporting Person was granted 6,250 restricted stock units ("RSUs") pursuant to the Issuer's 2021 Equity Incentive Plan, which RSUs will vest in full on the earlier of (i) the one-year anniversary of the date of grant, and (ii) the date that the Issuer's 2027 annual meeting of stockholders (the "2027 Annual Meeting") is held, subject to the Reporting Person's continued service with the Issuer.
Footnote F2
The Reporting Person is the sole member of VERITAS LIBERABIT VOS, LLC and in such capacity has the right to vote and dispose of the securities held by such entity. The Reporting Person disclaims beneficial ownership of the securities held by VERITAS LIBERABIT VOS, LLC, except to the extent of his pecuniary interest therein.
Footnote F3
The Reporting Person is the sole member of Signature Collection Properties, LLC and in such capacity has the right to vote and dispose of the securities held by such entity. The Reporting Person disclaims beneficial ownership of the securities held by Signature Collection Properties, LLC, except to the extent of his pecuniary interest therein.
Footnote F4
The stock option will vest in substantially equal monthly installments over the 12 months following the date of grant (or, in the event the 2027 Annual Meeting occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the stock option will vest on the date of such 2027 Annual Meeting), subject to the Reporting Person's continued service on the Issuer's Board through the applicable vesting date.